CLGN

CollPlant Biotechnologies Ltd. (CLGN) Management Analysis (2026)

Invetso Score: 2/10 — Weak · Last Updated: 2026-09-01

Overall Score

Leadership Governance

Management remains under pressure as CLGN continues to post deeply negative profitability metrics, with net profit margin at -33.8% and return on equity at -160.3%.

Liquidity is adequate for now, with a current ratio of 2.27 and cash per share of 3.10, but the business still shows weak operating efficiency and no dividend support.

Execution Capital Allocation

Execution remains poor, with operating margin at -33.3% and operating cash flow still negative at -4.74x sales.

Capital allocation appears constrained by ongoing losses, though leverage is modest with debt-to-equity at 0.54 and net debt to EBITDA near 0.13.

Incentives Shareholder Alignment

No material evidence of improved shareholder alignment is visible in the latest financials.

The company remains unprofitable, with negative free cash flow per share of -8.44 and no dividend yield.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on CollPlant Biotechnologies Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →